围手术期异体红细胞输注与全髋和全膝关节置换术后手术部位感染相关
该研究基于单家医院系统2000至2011年间6,788例初次或翻修全髋或全膝关节置换术患者,发现异体红细胞输注与术后1年内手术部位感染呈剂量依赖性关联,输注1、2、3和>3个单位时OR分别为1.97、2.20、3.66和7.40;术前贫血及已知出血或凝血障碍是需输注异体红细胞的风险因素。
要点
- 异体红细胞输注与全髋或全膝关节置换术后手术部位感染呈剂量依赖性关联,输注>3个单位时OR=7.40。
- 术前贫血(OR=3.90)、出血性疾病(OR=2.09)和凝血障碍(OR=1.37)是需输血独立风险因素。
- 作者强调术前风险评估、限制手术组织损伤和优化血液保护策略的必要性。
核心结论
- 异体红细胞输注与全髋或全膝关节置换术后手术部位感染风险呈剂量依赖性关系。
- 术前贫血或已知出血或凝血障碍是需异体红细胞输注的风险因素。
- 作者认为 findings 强调术前风险评估、限制手术组织损伤和优化血液保护策略的必要性。
研究设计与样本
- 单家医院系统2000至2011年间6,788例初次或翻修全髋或全膝关节置换术患者的回顾性队列研究。
- 采用多变量logistic回归模型确定异体红细胞输注与手术部位感染的独立关联。
- 证据等级:治疗性III级。
主要发现
- 控制内科合并症、计划手术、术前贫血和既存凝血障碍后,异体红细胞输注与手术部位感染呈剂量依赖性关联:输注1个单位OR=1.97(95%CI 1.38, 2.79;p<0.001),2个单位OR=2.20(95%CI 1.37, 3.44;p=0.002),3个单位OR=3.66(95%CI 1.72, 7.16;p=0.001),>3个单位OR=7.40(95%CI 4.91, 11.03;p<0.001)。
- 调整计划手术后,既存出血性疾病(OR=2.09;95%CI 1.57, 2.80;p<0.001)、凝血障碍(OR=1.37;95%CI 1.14, 1.64;p=0.001)和术前贫血(OR=3.90;95%CI 3.31, 4.61;p<0.001)均为需输注异体红细胞的独立风险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative allogeneic red blood-cell transfusion is a suspected risk factor for surgical site infection (SSI) after total joint arthroplasty (TJA), but the interrelationships among SSI risk, transfusion dose, preoperative anemia, and the presence of coagulopathies have not been well described. METHODS: Data on SSI within 1 year after surgery as well as on transfusion with blood products within 30 days after surgery were obtained for 6,788 patients who had undergone primary or revision total hip or knee arthroplasty from 2000 to 2011 in a single hospital system. Multivariate logistic regression modeling was used to determine the independent association between allogeneic red blood-cell transfusion and SSI. RESULTS: There was a dose-dependent association between allogeneic red blood-cell transfusion and SSI, with the infection rate increasing as the transfusion dose increased from 1 unit (odds ratio [OR] = 1.97; 95% confidence interval [CI] = 1.38, 2.79; p < 0.001), to 2 units (OR = 2.20; CI = 1.37, 3.44; p = 0.002), to 3 units (OR = 3.66; CI = 1.72, 7.16; p = 0.001), and to >3 units (OR = 7.40; CI = 4.91, 11.03; p < 0.001) after controlling for medical comorbidities, planned procedure, preoperative anemia, and preexisting coagulopathies. A preexisting bleeding disorder (OR = 2.09; CI = 1.57, 2.80; p < 0.001) and clotting disorder (OR = 1.37; CI = 1.14, 1.64; p = 0.001) and preoperative anemia (OR = 3.90; CI = 3.31, 4.61; p < 0.001) were all independent risk factors for transfusion after adjusting for the planned procedure. CONCLUSIONS: We found a dose-dependent relationship between allogeneic red blood-cell transfusion and SSI risk after total hip or knee arthroplasty. Additionally, preoperative anemia or a known bleeding or clotting disorder were risk factors for the need for allogeneic red blood-cell transfusion. Our findings underscore the need for preoperative risk assessment, methods to limit surgical tissue injury, and optimized blood conservation strategies. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Everhart JS, Sojka JH, Mayerson JL, et al. Perioperative Allogeneic Red Blood-Cell Transfusion Associated with Surgical Site Infection After Total Hip and Knee Arthroplasty. J Bone Joint Surg Am. 2018. PMID: 29462032. doi:10.2106/JBJS.17.00237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。